Search

This study proposes a hybrid model (Conformer-LSTM) based on Conformer and Long Short-Term Memory networks (LSTM) to overcome the limitations of existing techniques and enhance the accuracy and generalizability of wave height predictions. The model combines the advantages of self-attention mechanisms and convolutional neural networks. It captures global dependencies through multi-head self-attention and utilizes convolutional layers to extract local features, thereby enhancing the model’s adaptability to dynamic changes in time series. The LSTM component handles long-term dependencies, optimizing the coherence and stability of predictions. Additionally, an adaptive feature fusion weight network is introduced to further improve the model’s recognition and utilization efficiency of key features. Experimental data come from the National Oceanic and Atmospheric Administration buoy data, covering wave height, wind speed, and other data from key maritime areas. Evaluation metrics include Mean Absolute Error (MAE), Root Mean Square Error (RMSE), Mean Absolute Percentage Error (MAPE), and Coefficient of Determination (R2), ensuring a comprehensive assessment of model performance. The results show that the Conformer-LSTM model outperforms traditional LSTM, CNN, and CNN-LSTM models at multiple sites, confirming its potential in wave height prediction.

Lipid metabolic reprogramming is one of the hallmarks of hepatocarcinogenesis and development. Therefore, lipid-metabolism-related genes may be used as potential biomarkers for hepatocellular carcinoma (HCC). This study aimed to screen for genes with dysregulated expression related to lipid metabolism in HCC and explored the clinical value of these genes. We screened differentially expressed proteins between tumorous and adjacent nontumorous tissues of hepatitis B virus (HBV)-related HCC patients using a Nanoscale Liquid Chromatography–Tandem Mass Spectrometry platform and combined it with transcriptomic data of lipid-metabolism-related genes from the GEO and HPA databases to identify dysregulated genes that may be involved in lipid metabolic processes. The potential clinical values of these genes were explored by bioinformatics online analysis tools (GEPIA, cBioPortal, SurvivalMeth, and TIMER). The expression levels of the secreted protein (angiopoietin-like protein 6, ANGPTL6) in serum were analyzed by ELISA. The ability of serum ANGPTL6 to diagnose early HCC was assessed by ROC curves. The results showed that serum ANGPTL6 could effectively differentiate between HBV-related early HCC patients with normal serum alpha-fetoprotein (AFP) levels and the noncancer group (healthy participants and chronic hepatitis B patients) (AUC = 0.717, 95% CI: from 0.614 to 0.805). Serum ANGPTL6 can be used as a potential second-line biomarker to supplement serum AFP in the early diagnosis of HBV-related HCC.